AU Patent

AU2016213848A1 — Processes for making cyclic lipid implants for intraocular use

Assigned to Allergan Inc · Expires 2016-09-01 · 10y expired

What this patent protects

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. H:\tzm\Interwoven\NRPortbl\DCC\TZM\383220_1DOC - 8/8/13

USPTO Abstract

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. H:\tzm\Interwoven\NRPortbl\DCC\TZM\383220_1DOC - 8/8/13

Drugs covered by this patent

Lumigan (BIMATOPROST)

Patent Metadata

Patent number: AU2016213848A1
Jurisdiction: AU
Classification: —
Expires: 2016-09-01
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.